RecruitingPhase 1NCT05635643

Study of CHS-114 in Participants With Advanced Solid Tumors

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Sponsor

Coherus Oncology, Inc.

Enrollment

87 participants

Start Date

Dec 15, 2022

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor Head and Neck Squamous Cell Carcinoma

Summary

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new cancer drug called CHS-114 in people with a range of advanced solid tumors (cancers that form lumps, not blood cancers). It is an early-phase trial to evaluate safety and determine how the drug should be dosed. **You may be eligible if...** - You are 18 years or older - You have a locally advanced or metastatic (spread) solid tumor that has progressed after standard treatment options - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have only blood cancers (no solid tumors) - You do not have measurable disease - Your cancer has not been previously treated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCHS-114

CHS-114

DRUGtoripalimab

toripalimab-tpzi

Locations(16)

Hoag Memorial Hospital

Newport Beach, California, United States

FOMAT Medical Research

Oxnard, California, United States

Stanford Cancer Center

Palo Alto, California, United States

SCRI Lake Nona DDU (FL Cancer Specialists)

Orlando, Florida, United States

Emory Winship Cancer Institute

Atlanta, Georgia, United States

Hope & Healing Cancer Services

Hinsdale, Illinois, United States

University of Louisville

Louisville, Kentucky, United States

University of Maryland Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States

University of Michigan

Ann Arbor, Michigan, United States

Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center

Detroit, Michigan, United States

Washington University

St Louis, Missouri, United States

University of Cincinnati

Cincinnati, Ohio, United States

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

START- San Antonio

San Antonio, Texas, United States

START Mountain

West Valley City, Utah, United States

University of Washington/Fred Hutchinson Cancer Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05635643

Related Trials

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT0500540346 locations

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

NCT0714734817 locations

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT0625313057 locations

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT0576893217 locations

FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

NCT076383717 locations